18 September 2020
The second Russian COVID-19 vaccine created by the State Research Center of Virology and Biotechnology “Vector” forms immunity to the virus for at least six months, the chief of the center’s zoonotic infections and influenza section, Alexander Ryzhikov, said.
“The vaccine is built in such a way that it has no restrictions on repeat vaccination. It does not create lifelong immunity, which is good. It forms a targeted immune response, and there is no need to worry about long-term effects of revaccination. Immunity formed by this vaccine is enough for at least six months. In the future, revaccination is possible, the vaccine’s contents do not contradict that,” he said during a live feed on Instagram organized by the Russian consumer rights watchdog.
The expert added that the vaccine forms an immune response among a wide variety of coronavirus types.
The Vector Research Center received the approval of the Russian Health Ministry to carry out clinical trials of the vaccine on volunteers on July 24. On July 27, the first volunteer got the vaccine shot. On Monday, head of the Russian consumer rights watchdog Anna Popova informed that clinical trials of the COVID-19 vaccine developed by the Vector Research Center would conclude on September 30, after which, the post-registration trials will begin.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
The overall mortality rate of the population in Russia decreased by 7% in 2023
28 March 2024
Russia to collaborate with Hungary and Serbia in nuclear medicine
28 March 2024
Researchers propose novel test for pyrogen detection
27 March 2024
Parkinson’s infusion treatment demonstrates advantage over oral delivery
27 March 2024